Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead

Radhika Arya, Alex N Zimmet, Marisa Holubar, William Alegria · 2025

Read Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead by Radhika Arya, Alex N Zimmet, Marisa Holubar, William Alegria (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12722561.txt.

Description

Radhika Arya and co-authors weigh how to handle returning gut infections if a key preventive antibody leaves the scene. Their 2025 paper deals with Clostridioides difficile, a leading cause of hospital diarrhea, which comes back in a fifth to a third of patients. Stewardship and better testing have trimmed rates, yet recurrence keeps rising.

The antibody, bezlotoxumab, shields the colon wall from the germ's toxin B. Trials cut recurrence from 26 to 16 percent when it rode alongside standard antibiotics. Guidelines endorsed it in 2021 for first and later recurrences, while noting the logistics are awkward. The authors map the challenges ahead without it, from cost and access to which patients lose the most protection.

Catalog record

CREATORRadhika Arya, Alex N Zimmet, Marisa Holubar, William Alegria
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE12 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12722561

Browse the full library · About the Tower of Babel